Role of endogenous CYP450 metabolites of arachidonic acid in maintaining the glomerular protein permeability barrier

American Journal of Physiology - Renal Physiology

Volumn 293, Issue 2, 2007, Pages

  Williams, Jan Michael ^a   Sharma, Mukut ^a   Anjaiahh, Siddam ^b   Falck, John R ^b   Roman, Richard J ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

20 hydroxyeicosatetraenoic acid; Epoxyeicosatetraenoic acids; Glomerular permeability to albumin; Glomeruli; HET0016; N methylsulfonyl 6 (2 propargyloxyphenyl)hexanamide

Indexed keywords

20 HYDROXYEICOSADIEONIC ACID; 20 HYDROXYICOSATETRAENOIC ACID; ALBUMIN; AMIDE; ARACHIDONIC ACID; CYTOCHROME P450; EPOXYICOSATRIENOIC ACID; FORMAMIDINE; HYDROXY FATTY ACID; N HYDROXY N' (4 BUTYL 2 METHYLPHENYL)FORMAMIDINE; N METHYLSULFONYL 6 (2 PROPARGYLOXYPHENYL)HEXANAMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME SUBSTRATE; FATTY ACID METABOLISM; GLOMERULUS FILTRATION; MALE; NONHUMAN; PERMEABILITY BARRIER; PRIORITY JOURNAL; RAT;

EID: 34548435752     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00131.2007     Document Type: Article

References (31)

1. Abbate M, Zoja C, Morigi M, Rottoli D, Angioletti S, Tomasoni S, Zanchi C, Longaretti L, Donadelli R, Remuzzi G. Transforming growth factor-β1 is up-regulated by podocytes in response to excess intraglomerular passage of proteins: a central pathway in progressive glomerulosclerosis. Am J Pathol 161: 2179-2193, 2002.
2. Alonso-Galicia M, Falck JR, Reddy KM, Roman RJ. 20-HETE agonists and antagonists in the renal circulation. Am J Physiol Renal Physiol 277: F790-F796, 1999.
3. 1 excess as a mechanism for increased prevalence. Curr Hypertens Rep 2: 184-191, 2000.
4. Dahly-Vernon AJ, Sharma M, McCarthy ET, Savin VJ, Ledbetter SR, Roman RJ. Transforming growth factor-β, 20-HETE interaction, and glomerular injury in Dahl salt-sensitive rats. Hypertension 45: 643-648, 2005.
5. Dunn BR, Zatz R, Rennke HG, Meyer TW, Anderson S, Brenner BM. Prevention of glomerular capillary hypertension in experimental diabetes mellitus obviates functional and structural glomerular injury. J Hypertens Suppl 4: S251-S254, 1986.
6. Dworkin LD, Feiner HD, Randazzo J. Glomerular hypertension and injury in desoxycorticosterone-salt rats on antihypertensive therapy. Kidney Int 31: 718-724, 1987.
7. Hoagland KM, Alonso-Galicia M, Fenoy FJ, Jacob HJ, Garret MR, Roman RJ. Altered blood pressure and renal function in chromosome 5 congenic Dahl salt-sensitive rats. J Hypertens 18: S10, 2000.
8. Imig JD, Inscho EW, Deichmann PC, Reddy KM, Falck JR. Afferent arteriolar vasodilation to the sulfonimide analog of 11,12-epoxyeicosatrienoic acid involves protein kinase A. Hypertension 33: 408-413, 1999.
9. Ito O, Alonso-Galicia M, Hopp KA, Roman RJ. Localization of cytochrome P-450 4A isoforms along the rat nephron. Am J Physiol Renal Physiol 274: F395-F404, 1998.
10. Ito O, Roman RJ. Regulation of P-450 4A activity in the glomerulus of the rat. Am J Physiol Regul Integr Comp Physiol 276: R1749-R1757, 1999.
11. Iversen BM, Amann K, Kvam FI, Wang X, Ofstad J. Increased glomerular capillary pressure and size mediate glomerulosclerosis in SHR juxtamedullary cortex. Am J Physiol Renal Physiol 274: F365-F373, 1998.
12. McCarthy ET, Sharma R, Sharma M. Protective effect of 20-hydroxyeicosatetraenoic acid (20-HETE) on glomerular protein permeability barrier. Kidney Int 67: 152-156, 2005.
13. Miyata N, Taniguchi K, Seki T, Ishimoto T, Sato-Watanabe M, Yasuda Y, Doi M, Kametani S, Tomishima Y, Ueki T, Sato M, Kameo K. HET0016, a potent and selective inhibitor of 20-HETE synthesizing enzyme. Br J Pharmacol 133: 325-329, 2001.
14. Muller DN, Theuer J, Shagdarsuren E, Kaergel E, Honeck H, Park JK, Markovic M, Barbosa-Sicard E, Dechend R, Wellner M, Kirsch T, Fiebeler A, Rothe M, Haller H, Luft FC, Schunck WH. A peroxisome proliferator-activated receptor-alpha activator induces renal CYP2C23 activity and protects from angiotensin II-induced renal injury. Am J Pathol 164: 521-532, 2004.
15. +-ATPase. J Clin Invest 99: 1224-1230, 1997.
16. Palmer BF. Impaired renal autoregulation: implications for the genesis of hypertension and hypertension-induced renal injury. Am J Med Sci 321: 388-400, 2001.
17. Savin VJ, Sharma R, Lovell HB, Welling DJ. Measurement of albumin reflection coefficient with isolated rat glomeruli. J Am Soc Nephrol 3: 1260-1269, 1992.
18. Shankland SJ, Ly H, Thai K, Scholey JW. Increased glomerular capillary pressure alters glomerular cytokine expression. Circ Res 75: 844-853, 1994.
19. Sharma R, Khanna A, Sharma M, Savin VJ. Transforming growth factor-β1 increases albumin permeability of isolated rat glomeruli via hydroxyl radicals. Kidney Int 58: 131-136, 2000.
20. Shatara RK, Quest DW, Wilson TW. Fenofibrate lowers blood pressure in two genetic models of hypertension. Can J Physiol Pharmacol 78: 367-371, 2000.
21. Simons JL, Provoost AP, Anderson S, Rennke HG, Troy JL, Brenner BM. Modulation of glomerular hypertension defines susceptibility to progressive glomerular injury. Kidney Int 46: 396-404, 1994.
22. Snyder RW, Berns JS. Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease. Semin Dial 17: 365-370, 2004.
23. Sun CW, Falck JR, Harder DR, Roman RJ. Role of tyrosine kinase and PKC in the vasoconstrictor response to 20-HETE in renal arterioles. Hypertension 33: 414-418, 1999.
24. Van Dokkum RP, Alonso-Galicia M, Provoost AP, Jacob HJ, Roman RJ. Impaired autoregulation of renal blood flow in the fawn-hooded rat. Am J Physiol Regul Integr Comp Physiol 276: R189-R196, 1999.
25. Vera T, Taylor M, Bohman Q, Flasch A, Roman RJ, Stec DE. Fenofibrate prevents the development of angiotensin II-dependent hypertension in mice. Hypertension 45: 730-735, 2005.
26. Wang MH, Brand-Schieber E, Zand BA, Nguyen X, Falck JR, Balu N, Schwartzman ML. Cytochrome P450-derived arachidonic acid metabolism in the rat kidney: characterization of selective inhibitors. J Pharmacol Exp Ther 284: 966-973, 1998.
27. Williams JM, Zhao X, Wang MH, Imig JD, Pollock DM. Peroxisome proliferator-activated receptor- activation reduces salt-dependent hypertension during chronic endothelin B receptor blockade. Hypertension 46: 366-371, 2005.
28. Wilson TW, Alonso-Galicia M, Roman RJ. Effects of lipid-lowering agents in the Dahl salt-sensitive rat. Hypertension 31: 225-231, 1998.
29. Yu M, Alonso-Galicia M, Sun CW, Roman RJ, Ono N, Hirano H, Ishimoto T, Reddy YK, Katipally KR, Reddy KM, Gopal VR, Yu J, Takhi M, Falck JR. 20-Hydroxyeicosatetraenoic acid (20-HETE): structural determinants for renal vasoconstriction. Bioorg Med Chem 11: 2803-2821, 2003.
30. Yu Z, Davis BB, Morisseau C, Hammock BD, Olson JL, Kroetz DL, Weiss RH. Vascular localization of soluble epoxide hydrolase in the human kidney. Am J Physiol Renal Physiol 286: F720-F726, 2004.
31. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 77: 1925-1930, 1986.